Xingguo Liu

New Capabilities

Active researcher at GIBH

For most of modern medicine's history, diseases caused by defective mitochondria — the structures inside cells that generate energy — have been essentially untreatable. Doctors could manage symptoms, but the broken power plants themselves were beyond reach. Now, within a six-month span, the United States Food and Drug Administration (FDA) has approved the first two drugs targeting mitochondrial diseases, and a Chinese research team has demonstrated a method to physically transplant healthy mitochondria into diseased cells with sixteen times the efficiency of previous approaches.

Updated 3 hours ago